CompletedPhase 3

TARGETING DUAL PATHWAYS IN REFRACTORY COCCYDYNIA

Turkey (Türkiye)60 participantsStarted 2022-06-01

Plain-language summary

This retrospective cohort study included 60 patients aged 18-65 years treated at a tertiary pain clinic between June 2022 and June 2024. Patients received either Ganglion Impar Block (GIB) alone or GIB combined with pericoccygeal injection in a single session under fluoroscopic guidance. Pain severity and functional outcomes were assessed using the Numeric Rating Scale (NRS-11), Oswestry Disability Index (ODI), and Paris Functional Coccydynia Impact Questionnaire (PFCIQ) before the procedure and at 1 and 3 months post-intervention.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * with a confirmed diagnosis of coccydynia persistent for at least 3 months as determined by history, clinical examination, and radiological imaging, who had undergone either GIB or GIB with pericoccygeal injection, and had complete medical records available for review between June 2022 and June 2024. Exclusion Criteria: * having a recent intervention (in the past 6 months), morbid obesity (BMI \> 35 kg/m²), severe comorbidities, skin infections, bleeding disorders, pregnancy, or having incomplete records

What they're measuring

Pain Assessment with Numeric Rating Scale 11

Timeframe: From the beginning of the treatment to the 3 month follow-up

Trial details

NCT IDNCT07060313

SponsorIstanbul University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-01

View on ClinicalTrials.gov More Coccydynia trials